FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics, namely to a method of treating or preventing cancer, comprising administering to a human patient an effective amount of an antibody having the ability to bind to CLDN18.2 and mediating the destruction of cells expressing CLDN18.2, wherein said cancer is CLDN18.2 positive cancer, and wherein the antibody is administered in at least three doses at time intervals of at least 7 days and is administered in a dose of at least 300 mg/m2.
EFFECT: treating cancer, the cells of which express CLDN18.2, in humans.
20 cl, 10 dwg, 19 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| ANTI-CLDN ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND A METHOD OF ITS DETECTION | 2020 |
|
RU2801315C2 |
| NOVEL ANTI-CLDN18.2 ANTIBODIES | 2020 |
|
RU2830887C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| ANTI-CLAUDIN ANTIBODIES AND USE THEREOF | 2019 |
|
RU2815926C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
